FDA
-
-
-
-
-
-
-
NantHealth Announces FDA Marketing Authorization of Omics Core℠: The Nation’s First Tumor-Normal Mutation Profiling of Overall Tumor Mutational Burden from Whole Exome Sequencing in Solid Tumors
-
-
-
-
-
-
-
NantHealth Reports 2017 Third Quarter Financial Results; GPS Revenue Doubles from Preceding Quarter
-
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

